Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRONULIFE OraProtect
- Development stage
- Unknown
- Lead developer
- Glac Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
PRONULIFE OraProtect is a multi-strain probiotic ingredient developed by GLAC Biotech Co., Ltd. for oral health and microbiome support. The formulation, specifically the OraProtect-L variant, incorporates three high-quality strains: *Lactobacillus salivarius* AP-32, *Lactobacillus plantarum* LPL28, and *Lactobacillus paracasei* ET-66. It is designed to inhibit key dental plaque-forming pathogens, including *Streptococcus mutans*, *Porphyromonas gingivalis*, and *Fusobacterium nucleatum*, while simultaneously enhancing local immunity by stimulating the secretion of salivary Immunoglobulin A (IgA). The product utilizes GLAC's proprietary PRONEX micro-encapsulation technology to ensure strain stability and quality throughout its shelf life. Clinical validation has demonstrated its efficacy in improving symptoms of gum inflammation, mouth ulcers, and throat inflammation, as well as optimizing the oral microbiota balance. It is intended for use as a dietary supplement or functional food ingredient and has received therapeutic approval in Australia (ARTG ID 329570).
- Brand names
- PRONULIFE OraProtectOraProtect-L
- Other names
- OraProtect
02
Targets
IgA (Immunoglobulin A)
Beyond the preview
Go deeper on PRONULIFE OraProtect.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRONULIFE OraProtect.